Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2007 | 12-2006 | 09-2006 | 06-2006 | 03-2006 | |
| Sales | 7,217 | 6,981 | 8,211 | 6,021 | 5,717 |
| Gross Profit | 7,217 | 6,981 | 8,211 | 6,021 | 5,717 |
| Operating Expenses | 31,211 | 16,972 | 16,815 | 17,130 | 15,514 |
| Operating Income | -23,994 | 6,981 | -8,604 | -11,109 | -9,797 |
| Interest Expense | 286 | 296 | 265 | 230 | 238 |
| Other Income | 2,635 | 296 | 1,469 | 1,429 | 1,175 |
| Pre-tax Income | -21,645 | 6,981 | -7,400 | -9,910 | -8,860 |
| Net Income Continuous | -21,645 | 6,981 | -7,400 | -9,910 | -8,860 |
| Net Income | $-21,645 | $6,981 | $-7,400 | $-9,910 | $-8,860 |
| EPS Basic Total Ops | -0.58 | -0.25 | -0.23 | -0.31 | -0.30 |
| EPS Basic Continuous Ops | -0.58 | -0.25 | -0.23 | -0.31 | -0.30 |
| EPS Diluted Total Ops | -0.58 | -0.25 | -0.23 | -0.31 | -0.30 |
| EPS Diluted Continuous Ops | -0.58 | -0.25 | -0.23 | -0.31 | -0.30 |
| EBITDA(a) | $-22,799 | $-8,789 | $-6,613 | $-11,116 | $-8,913 |